Actively Recruiting
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
Led by University of South Florida · Updated on 2019-08-19
40
Participants Needed
1
Research Sites
179 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this pilot study is to explore the efficacy of chloroquine in terminating persistent AF and assess its potential role as a pharmacological cardioversion agent for the management of AF.
CONDITIONS
Official Title
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years and older
- History of symptomatic persistent atrial fibrillation lasting more than 7 days but less than 12 months
- AF documented by ECG, event monitoring, loop recorder, telemetry, trans-telephonic monitoring, pacemaker, or cardiac defibrillator readouts within 24 months prior to enrollment
- Currently on anticoagulation therapy as per local guidelines for stroke prevention
- Implanted dual chamber pacemaker or ICD capable of monitoring atrial arrhythmias or willingness to wear a 2-week event monitor
- Signed informed consent
You will not qualify if you...
- Age under 18 years
- AF caused by a reversible condition such as acute myocardial infarction, pulmonary embolism, recent surgery, pericarditis, alcohol intoxication, hypoxemia, or thyrotoxicosis
- Structural heart disease including artificial heart valves or valvular AF
- Obstructive coronary artery disease or history of myocardial infarction
- Ejection fraction below 50% within 1 year of consent
- Moderate to severe aortic or mitral valve disease
- Prolonged QTc over 460 msec on baseline ECG
- Contraindications or allergy to quinolines or chloroquine
- Use of amiodarone within 12 months prior to enrollment
- AF ablation within 30 days before enrollment
- Renal impairment (eGFR less than 30 mL/min/1.73 m2 or serum creatinine over 1.25 mg/dL) if older than 65
- Hepatic disease with ALT/AST twice the upper normal limit
- History of alcohol or drug abuse
- Pre-existing auditory damage
- History of epilepsy
- Women of child-bearing potential who are pregnant, breastfeeding, planning pregnancy, not surgically sterile, or not using two effective birth control methods
- Current participation in another clinical study
- Serious or active medical or psychiatric condition interfering with study participation
- Unable to stop medications that interact significantly with chloroquine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of South Florida
Tampa, Florida, United States, 33606
Actively Recruiting
Research Team
T
Thanh Tran, MPH
CONTACT
S
Sami Noujaim, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here